A number of research firms have changed their ratings and price targets for Biogen (NASDAQ: BIIB):

  • 10/23/2017 – Biogen was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They wrote, “We’re downgrading the stock to neutral from buy as we don’t think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene’s Ozanimod launch,”
  • 10/23/2017 – Biogen had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $390.00 price target on the stock.
  • 10/23/2017 – Biogen is now covered by analysts at Guggenheim. They set a “buy” rating on the stock.
  • 10/18/2017 – Biogen had its price target raised by analysts at Bank of America Corporation from $358.00 to $365.00. They now have a “buy” rating on the stock.
  • 10/17/2017 – Biogen was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $415.00 price target on the stock, up previously from $300.00. They wrote, “gigantic” aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a “no news is good news” scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn’t reported anything negative.Second, Biogen’s partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen’s often ignored stroke programs address a very large market. Of particular note, the company’s Tysabri stoke program uncovered the “same cognitive and energy benefits in stroke patients that are routinely reported in MS patients” and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company’s base business is “meh not mud,” the analyst added. The therapy remains a drug with “remarkable anti inflammatory properties,” but a commercial rollout will likely be “measured.”
  • 10/17/2017 – Biogen was upgraded by analysts at Mizuho from a “neutral” rating to a “buy” rating. They now have a $400.00 price target on the stock, up previously from $319.00.
  • 10/17/2017 – Biogen had its “buy” rating reaffirmed by analysts at Morgan Stanley.
  • 10/12/2017 – Biogen had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $300.00 price target on the stock.
  • 10/5/2017 – Biogen was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $375.00 price target on the stock, up previously from $311.00.
  • 10/5/2017 – Biogen had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $315.00 price target on the stock.
  • 10/2/2017 – Biogen had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $319.00 price target on the stock. They wrote, “We looked through early Spinraza data to draw as close to apples to apples comparison as possible. Here is a chart we found (from an old BIIB deck), which shows Spinraza increases SMN protein by ~2.7x.””
  • 9/21/2017 – Biogen was downgraded by analysts at Raymond James Financial, Inc. from a “strong-buy” rating to a “market perform” rating. They now have a $319.00 price target on the stock, up previously from $244.28.
  • 9/20/2017 – Biogen is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $360.00 price target on the stock.
  • 9/14/2017 – Biogen is now covered by analysts at Royal Bank Of Canada. They set a “sector perform” rating and a $319.00 price target on the stock.
  • 9/13/2017 – Biogen had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $319.00 price target on the stock, up previously from $274.00.
  • 9/13/2017 – Biogen had its price target raised by analysts at BMO Capital Markets from $328.00 to $377.00. They now have a “market perform” rating on the stock.
  • 9/7/2017 – Biogen was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $346.83 price target on the stock.
  • 9/4/2017 – Biogen was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $316.82 price target on the stock.
  • 9/1/2017 – Biogen was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/29/2017 – Biogen was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $319.53 price target on the stock.
  • 8/25/2017 – Biogen had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $290.00 price target on the stock.

Shares of Biogen Inc. (NASDAQ BIIB) opened at 328.55 on Tuesday. The company’s 50 day moving average is $324.86 and its 200-day moving average is $286.43. Biogen Inc. has a 1-year low of $244.28 and a 1-year high of $348.84. The stock has a market capitalization of $69.47 billion, a price-to-earnings ratio of 21.56 and a beta of 0.77.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, beating the consensus estimate of $4.36 by $0.68. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The company’s revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the company posted $5.21 EPS. Equities analysts anticipate that Biogen Inc. will post $21.65 earnings per share for the current fiscal year.

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.